Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

In addition, the proportion of muscle-invasive bladder cancer was limited and ... value in locally advanced invasive or metastatic urothelial cancer.

Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed ...

In urothelial bladder cancer, increased T cell infiltration has been correlated with longer patient survival. Previous clinical studies with an FGFR inhibitor, rogaratinib, demonstrated that the ...

In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients ...

Opens in a new tab or window In the U.S., the economic burden associated with the latest first-line treatments for locally advanced or metastatic urothelial carcinoma (la/mUC) is significant.

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical trial, and ...

Undetectable pre-cystectomy ctDNA predicts better pathological outcomes post-radical cystectomy Patients with undetectable pre-cystectomy status demonstrated recurrence-free survival, regardless of ...